Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

potential proposals from selected parties regarding various financial or strategic alternatives. Our management and Board of Directors continue to believe a transaction of significant size and scope may be necessary to meaningfully address liquidity concerns and the working capital needs of our business. There can be no assurance that we will be able to complete any transaction, or that any transaction could be pursued or would be able to be completed on favorable terms.

Our cash inflows and the amounts of expenditures that will be necessary to execute our business plan are subject to numerous uncertainties, including but not limited to: changes in drug-eluting coronary stent markets, including the impact of new competitive entrants into such markets, and the sales achieved in such markets by our partner BSC, the amount, timing and success of product sales and marketing initiatives and new product launches, the timing and success of our research, product development and clinical trial activities, the timing of completing certain operational initiatives, our ability to effect reductions in certain aspects of our budgets in an efficient and timely manner, and changes in interest rates. These and other uncertainties may adversely affect our liquidity and capital resources to a significant extent and may force us to further reduce our expenditures on research and development or on our various new product and sales and marketing initiatives in order for us to continue to service our debt obligations. Such further reductions in our budgeted expenditures may have an adverse effect on our new product development and sales growth initiatives and reduce our ability to achieve the revenue growth targets, product launch or new product development timelines in our current operating plan. There can also be no assurance that such reductions in expenditures will be adequate to provide enough cash flow to continue to service our current level of debt obligations.

In
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... 1, 2015 About Bio-alcohols ... sugar or cellulose. Bio-alcohols are primarily used in the ... a replacement for gasoline in cars. Technavio,s analysts forecast ... of 9 percent over the period 2014-2019. ... can be segmented into five: transportation, infrastructure, medical, and ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Regis ... and manufacturing of chiral stationary phases (CSPs) for ... for its current and presenting solutions for new ... its portfolio. This valuable addition to its core ... effective advantage that can tackle projects for the ...
(Date:6/1/2015)... ROCHESTER, Minn. and SOUTH SAN ... Baxter Ventures, the venture arm of Baxter International Inc. ... Pharmaceutical Development, LLC ("VPD") today announced the formation of ... model initiated by Baxter Ventures to focus on the ... of immunology, hematology, and oncology. Following the spin-off of ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Global Bio-alcohols Market 2015-2019 2Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5
... Campaign for Cancer Prevention (CCP) began in 2007 with the ... about preventing cancer.  It has now grown to a more ... the social media platform, Causes.com. Nearly five years later, CCP ... a Harvard Medical School flagship teaching hospital, with all campaign ...
... 2011 Redwood Bioscience, a biopharmaceutical company developing ... conjugates, announced the appointment of Peter Van Vlasselaer, ... Directors.  In this role, Dr. Van Vlasselaer will ... development as well as corporate strategy.  Dr. Van ...
... LAGUNA NIGUEL, Calif., Oct. 3, 2011 Inspiration Biopharmaceuticals, ... (EMA) has validated and accepted the filing of the ... factor IX (FIX) product for the treatment and prevention ... so, the EMA has verified that it will begin ...
Cached Biology Technology:Campaign for Cancer Prevention Connects 6 Million+ Members on Facebook Causes to Groundbreaking Research at Brigham and Women's Hospital 2Campaign for Cancer Prevention Connects 6 Million+ Members on Facebook Causes to Groundbreaking Research at Brigham and Women's Hospital 3Campaign for Cancer Prevention Connects 6 Million+ Members on Facebook Causes to Groundbreaking Research at Brigham and Women's Hospital 4Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman 2Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B 2Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B 3
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/26/2015)... Research and Markets ( ... "Saudi Arabia Biometric Systems Market Forecast and ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... to grow at over 22% CAGR through 2020 ... the surging demand for better biometric technologies in ...
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... healthy diets through adolescence than their peers who do not drink ... study showed that girls who drank soda at age five had ... duration of the study, which ended at age 15. Girls who ... nutritional requirements, but their diets were healthier. The difference between ...
... The WHO Fracture Risk Assessment Tool (FRAX) is now easily ... access and easy to use in any clinical setting. ... year probability of a major osteoporotic event, The 10 year ... users, NOGG guidance is accessible. This provides a guide for ...
... WASHINGTON, DC A new analysis by the ... that the U.S. government has spent around $430 million ... the Department of Energy funding a majority of the ... European Union and three individual European countries the ...
Cached Biology News:Early consumption of soda indicator of unhealthy diet 2Early consumption of soda indicator of unhealthy diet 3
... to significantly increase the shelf life of ... increased at room temperature storage conditions in ... is subjected to 0.45 micron filtration, and ... formulation insures consistently high levels of activity ...
... ThermoStat Plus accurately and conveniently controls the temperature ... maintains different temperature levels up to 99 C*, ... temperatures as low as 5 C. The thermoblocks ... ml tubes, and microplates enable a high degree ...
... to significantly increase the shelf life of ... increased at room temperature storage conditions in ... is subjected to 0.2 micron filtration, and ... formulation insures consistently high levels of activity ...
...
Biology Products: